Two generic enzyme immunoassays (EIAs) were developed for detection of anti-hepatitis delta virus antibodies (anti-HD) and compared with a commercially available radioimmunoassay. Both generic assays were configured as blocking assays and used hepatitis delta antigen (HDAg) derived from infected chimpanzee liver (EIA-1) or from Escherichia coli transformed with a plasmid containing an insert from within an open reading frame encoding HDAg (EIA-2). Absolute sensitivity was ascertained by endpoint titration, which demonstrated essentially identical endpoints for EIA-1 and EIA-2. The absolute sensitivities of the EIAs were approximately four times greater than that of the radioimmunoassay. Specificity and sensitivity were ascertained by testing a panel of 176 serum specimens by each assay. The specimens were selected to represent a panel composed of sera from individuals with or without markers of viral hepatitis as follows: (i) serologically confirmed by exclusion as posttransfusion non-A, non-B hepatitis; (ii) acute or chronic hepatitis B virus infection, positive for hepatitis B surface antigen; (iii) resolved hepatitis B virus infection, positive for anti-hepatitis B surface antigen; (iv) acute hepatitis A virus infection, positive for anti-hepatitis A virus immunoglobulin M; and (v) normal human sera. All three assays for anti-HD gave similar specificity and sensitivity values. In conclusion, the recombinant expressed HDAg can replace antigen derived from infected liver tissue as a diagnostic reagent used to configure an EIA for detection of anti-HD. Furthermore, the results suggest that the expressed antigen contains the important immunodominant epitope(s).
Hepatitis delta virus (HDV) is a transmittable agent which depends on hepatitis B virus (HBV) for its expression and replication. HDV was discovered by Rizzetto et al. in 1977 (6) by immunofluorescence of biopsy materials obtained from chronic HBV carriers. Infection with HDV may occur simultaneously with HBV infection (coinfection) or in chronic carriers of hepatitis B surface antigen (HBsAg; superinfection) and has been shown to cause both chronic progressive and fulminant hepatitis in a significant number of cases. HDV is transmitted by the parenteral route through direct contact with contaminated blood or blood products and through intimate contact by transmucosal exchange of body fluids. In Western countries, the groups at high risk are intravenous drug users, hemophiliacs, posttransfusion and hemodialysis patients, male homosexuals who have multiple partners, and the sexual partners of these high-risk groups (for a review, see S. C. Hadler and H. A. Fields, in R. B. Belshe, ed., Textbook of Human Virology, in press).
The diagnosis of HDV infection is usually established by detection of corresponding total and immunoglobulin M (IgM) class antibodies (anti-HD) in serum. To detect total anti-HD activity, various blocking and competitive inhibition radioimmunoassays (RIAs) (7) and enzyme immunoassays (EIAs) (1-3, 9) have been developed. These assays measure the decrease in the specific binding of radio-or enzyme-labeled anti-HD IgG due to anti-HD immunoglobulin activity in serum. All reported tests use HDV antigen (HDAg) derived from either infected liver or infectious serum of humans or animals (e.g., chimpanzees and woodchucks). The relative rarity of these materials is a major drawback in maintaining a reliable source of quality reagents.
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Recently, the genome of HDV has been cloned and sequenced (4, 5, 8, 10) . At least five open reading frames have been elucidated, one of which has been shown to encode HDAg, which reacts specifically with the sera of HDV-infected individuals (10) .
We developed a blocking EIA to detect anti-HD configured with an antigen derived from Escherichia coli. This assay was compared with a commercially available RIA and another generic EIA, both of which use antigens derived from infected woodchuck and chimpanzee livers, respectively. MATERIALS conjugated to horseradish peroxidase by the meta-periodate oxidation method of Wilson and Nakane (11) . Specimens. Specimens were selected to represent a panel (n = 176) composed of sera from individuals with or without serologic markers of viral hepatitis as follows: (i) seriologically confirmed by exclusion, posttransfusion non-A, non-B (NANB) hepatitis (n = 13); (ii) acute or chronic HBV infection, positive for HBsAg (n = 54); (iii) resolved HBV infection, positive for antibodies to HBsAg (n = 17); (iv) acute hepatitis A virus (HAV) infection, positive for anti-HAV IgM (n = 17); and (v) normal human sera (NHS) (n = 75). All serological tests were performed with either RIA or EIA kits obtained from Abbott Laboratories.
Anti-HD EIA. The generic EIAs using antigen derived from infected liver tissue (EIA-1) or recombinant expressed antigen (EIA-2) were configured essentially as previously described (2) . Briefly, microtiter wells (Immulon I; Dynatech Laboratories, Chantilly, Va.) were coated with 125 ,ul of anti-HD diluted in 0.05 M carbonate buffer, pH 9.6, and incubated overnight at room temperature. The wells were then aspirated and washed three times with phosphatebuffered saline, pH 7.2, containing 0.5% bovine serum albumin (PBS-BSA). Each well then received an optimal dilution (predetermined by checkerboard analysis) of HDAg derived either from a chimpanzee liver or from E coli. The wells were incubated for 2 h at 45°C and then washed with PBS-BSA. Each well then received 100 ,ul of a specimen and was incubated for 1 h at 37°C. After a wash cycle, 100 ,ul of anti-HD IgG conjugated to horseradish peroxidase optimally diluted (as predetermined by checkerboard analysis) in phosphate-buffered saline containing 25% NHS was added and incubated for 1 h at 37°C. After a wash cycle, 200 piu of o-phenylenediamine-H202 dissolved in phosphate-citrate buffer (pH 5.0) was added, incubated for 30 min in the dark, and stopped by addition of 50 ,ul of 4 N H2SO4, and the optical density at 490 nm (OD490) was photometrically read. A specimen was considered positive whenever the OD490 was reduced by greater than 50% of that of the negative control specimens, which yielded OD490 values of about 1.0 (adjusted to this value by checkerboard analysis).
Anti-HD RIA. A commercially available anti-HD RIA (Abbott Laboratories) was compared with both EIA-1 and EIA-2. The RIA is a competitive inhibition assay and uses HDAg derived from infected woodchuck livers. The cutoff value was determined as described in the package insert and was equal to 0.4 times the average of the negative controls plus 0.6 times the average of the positive controls. <Acute posttransfusion NANB infection specimen. RESULTS Sensitivity. To determine absolute sensitivity, endpoint titers with each assay configuration were determined on three anti-HD-positive human sera representing highly, moderately, and weakly positive specimens. Each specimen was serially diluted fourfold in NHS and tested in triplicate, and the results were averaged. A P/N ratio was calculated for each dilution. This ratio was defined as the signal value of the specimen (OD490 for EIA; counts per minute for RIA) divided by the signal value of the negative controls. This allowed the RIA and EIA values to be expressed in the same manner and thus directly compared. The absolute sensitivities of both EIA-1 and EIA-2 were essentially identical and about four times greater than that of the RIA (Fig. 1 a to c) .
Frequency distribution of EIA-2. The frequency distribution of the EIA using recombinant expressed antigen was ascertained by testing 176 sera (Table 1 ; Fig. 2 (Fig. 2) . The 50% cutoff was equivalent to the mean of the negative controls minus 6 standard deviations of the negative controls, thereby making the 50% cutoff value highly statistically significant. Four of the specimens positive for HBsAg yielded P/N values for anti-HD activity within this grey zone. Since HDV infection can occur only in the presence of HBV infection, these four sera could be classified as true positives.
Specificity and sensitivity. Specificity and sensitivity were calculated with EIA-1 as the reference assay. EIA-2 was 100% specific and 94.3% sensitive compared with EIA-1. The RIA was 99.3% specific and 88.2% sensitive compared with EIA-1 ( Table 3 ). There were six discordant results, which are listed in Table 2 (no. 4 to 9). Two specimens (no. 4 and 6) were positive by EIA-1 and negative by EIA-2. Both of these specimens yielded P/N values in the grey zone for EIA-2, and specimen 6 was weakly positive by RIA. Therefore, these specimens may be discordant on the basis of slight differences in absolute sensitivity. Four specimens were negative by RIA and positive by EIA-1 (no. 4, 5, 7, and 8). Three of these specimens (no. 5, 7, and 8) were also very close to the RIA cutoff. Therefore, on the basis of the greater absolute sensitivity of EIA-1, these four specimens probably represent weakly positive anti-HD sera. Specimen 9 was positive by the less sensitive RIA and negative by both 50%(X 6.07SD) S3 -2 -1 _ Grey Zone EIA-1 and EIA-2. Because this specimen was also positive for HBsAg, the true anti-HD status remains unknown. DISCUSSION A close correlation was obtained among all three tests for anti-HD. The absolute-sensitivity assay demonstrated a four-times-higher absolute sensitivity for both EIA-1 and EIA-2 than for RIA. This may be due to differences between a competitive inhibition assay and a blocking assay rather than between RIA and EIA. The new test in our study (EIA-2), which uses recombinant expressed antigen, demonstrated excellent discrimination between positive and negative sera (Fig. 2) . The four anti-HD specimens in the grey zone in the HBsAg-positive group are most probably true positives with waning anti-HD activity. If one were to use a cutoff value based on the mean of the negative controls minus 3 standard deviations of the negative control, a valid statistical consideration, then these four specimens would be considered positive for anti-HD activity.
One of the specimens positive for anti-HD within the acute HAV infection group also tested positive for HBsAg and therefore represents a case of acute HAV infection in a chronic HBV carrier who is probably also a carrier of HDV. The other specimen positive for anti-HD found within the acute HAV infection group was negative for HBsAg but positive for anti-HBs and therefore probably represents a past coinfection with HBV and HDV with resolution of both infections.
The one specimen within the posttransfusion NANB hepatitis group which tested positive for anti-HD also tested positive for anti-HD by both EIA-1 and RIA (Table 2, no. 3). Because this specimen was negative for HBsAg but positive for anti-HBs and anti-HBc (data not shown), it represents a case of NANB hepatitis with a previous resolved HBV-HDV coinfection.
Using EIA-1 as the reference standard, we demonstrated that EIA-2 was both more sensitive and more specific than the RIA. In general, the discordant specimens among the three tests were all close to their cutoff values and therefore reflected differences in relative sensitivities.
This study presents data that suggest that recombinant expressed HDAg obtained in E. coli provides a satisfactory reagent for detection of anti-HD by a blocking EIA. Use of this reagent in assay configuration represents a theoretically unlimited supply of HDAg free from the potentially hazardous procedure involved with extraction and manipulation of antigen from infectious materials such as livers and sera. In addition, use of a recombinant expressed antigen assures a constant source of antigen of defined quality. Finally, our results also suggest that, because of essentially equivalent sensitivity and specificity data, recombinant expressed HDAg composed of 64 amino acids contains the most important immunodominant epitope(s).
